An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.

Already approved for lung cancer, BMS’s ROS1/NTKK inhibitor gets US FDA accelerated approval for solid tumors that are NTRK-fusion positive.

Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.

The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.